SERUM ANNEXIN A5 LEVELS DOESN'T SERVE A DISCRIMINATING MARKER OF LEFT VENTRICULAR EJECTION FRACTION IN PATIENTS WITH A RECENT ACUTE MYOCARDIAL INFARCTION

Background and Aim: Annexin A5 (anxA5) is a useful biomarker of cytotoxicity in conditions that associated with cellular necrosis. Its levels increased in heart failure that complicated hypertension. This study aimed to assess the serum levels of anxA5 in patients with a recent acute myocardial infarction (AMI) presented with variable values of left ventricle ejection fraction (EF).

Materials and Methods: A total number of 30 healthy (Group I) subjects and 80 patients (Group II) with AMI were recruited from the Teaching Hospital in Diyala, Iraq. Anthropometric measurements, the laboratory measurements included fasting serum lipid profile, and serum anxA5, and the echocardiographic data were determined.

Results: Serum anxA5 levels increased by 7 folds in Group II compared with Group I. There is an insignificant (p =.376) difference between in serum anxA5levels between patients with EF of < 55% and ≥ 55%. Nonsignificant correlations between serum anxA5 levels with EF (r=0.07, P=.537) or with E/A ratio (r=0.014, P=.313). Significant low levels of anxA5 observed in patients with anterior myocardial infarction (32.8±1.7 ng/ml) compared with inferior (37.5±1.1, p=0.034) or other sites (38.32±2.1, p=0.042).

Conclusion: Serum annexin A5 levels increased in AMI and its increment does not relate to the ejection fraction or E/A ratio but related to the infarction site.